SK Pharmteco Partners with OTXL to Tackle Rare Diseases

SK pharmteco has signed a collaborative agreement with the Orphan Therapeutics Accelerator (OTXL), a non-profit, biotech focused on completing development and enabling access to stalled rare disease treatments, to support the advancement of novel therapeutic programs.

The partnership is built on SK pharmteco’s Rare Disease Advancement Initiative, a commitment to accelerate programs addressing high unmet need and delivering therapies to patients faster with thoughtful commercial flexibility designed to support impact and long-term scalability. Under the terms of the agreement, SK pharmteco will serve as a preferred technical partner, providing critical technical capabilities to accelerate OTXL’s pipeline toward clinical and commercial milestones.

“We believe patients fighting rare diseases deserve the world’s most reliable and sophisticated manufacturing solutions,” said Joerg Ahlgrimm, CEO of SK pharmteco. “Rare disease programs often operate under compressed timelines and unique resource constraints, making dependable technical execution and adaptable partnerships critical. By combining our specialized manufacturing capabilities and deep technical expertise with OTXL’s programs, we are helping accelerate the development and delivery of critical therapies while reinforcing our position as a leading CDMO for rare diseases.”

As part of this arrangement, SK pharmteco will provide OTXL with prioritized access and preferential rates for up to two therapeutic programs per year. The collaborative framework encompasses a comprehensive suite of advanced manufacturing services, including:

• Process Development: Optimizing and scaling robust protocols tailored to complex modalities.
• Analytical Development: Designing precise assay methods to ensure safety and support molecular characterization.
• GMP Manufacturing & Quality Control Release: Ensuring the highest standards of regulatory compliance and product quality for clinical applications.

Craig Martin, Founder and CEO of OTXL, said, “SK pharmteco brings serious, global technical depth to our network, and their commitment to structuring access around the realities of rare disease development makes them a valued addition to the ecosystem we’re building.”

More OTXL News

Earlier this year, AGC Biologics joined OTXL’s Clinical Development Network as a manufacturing partner.